Follow this preprint
Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus Erythematosus
View ORCID ProfileYoshiya Tanaka, Atsushi Kumanogoh, Tatsuya Atsumi, Tomonori Ishii, View ORCID ProfileFumitoshi Tago, View ORCID ProfileMari Aoki, View ORCID ProfileShintaro Yamamuro, Shizuo Akira
doi: https://doi.org/10.1101/2024.04.26.24306410
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Yoshiya Tanaka
1University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Atsushi Kumanogoh
2Department of Respiratory Medicine and Clinical Immunology, Osaka University Faculty of Medicine Graduate School of Medicine, Osaka, Japan
Tatsuya Atsumi
3Department of Rheumatology, Endocrinology, and Nephrology, Hokkaido University, Sapporo, Japan
Tomonori Ishii
4Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan
Fumitoshi Tago
5Eisai Co., Ltd., Tokyo, Japan
Mari Aoki
5Eisai Co., Ltd., Tokyo, Japan
Shintaro Yamamuro
5Eisai Co., Ltd., Tokyo, Japan
Shizuo Akira
6Department of Host Defense, Osaka University Immunology Frontier Research Center, Osaka, Japan

DATA AVAILABILITY
Data are available upon reasonable request. The datasets used and/or analyzed during the current study are available from the corresponding author and sponsor on reasonable request.
Posted April 27, 2024.
Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus Erythematosus
Yoshiya Tanaka, Atsushi Kumanogoh, Tatsuya Atsumi, Tomonori Ishii, Fumitoshi Tago, Mari Aoki, Shintaro Yamamuro, Shizuo Akira
medRxiv 2024.04.26.24306410; doi: https://doi.org/10.1101/2024.04.26.24306410
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (412)
- Allergy and Immunology (726)
- Anesthesia (214)
- Cardiovascular Medicine (3112)
- Dermatology (263)
- Emergency Medicine (463)
- Epidemiology (13049)
- Forensic Medicine (13)
- Gastroenterology (862)
- Genetic and Genomic Medicine (4871)
- Geriatric Medicine (449)
- Health Economics (751)
- Health Informatics (3072)
- Health Policy (1109)
- Hematology (410)
- HIV/AIDS (963)
- Medical Education (453)
- Medical Ethics (120)
- Nephrology (502)
- Neurology (4639)
- Nursing (247)
- Nutrition (689)
- Oncology (2395)
- Ophthalmology (678)
- Orthopedics (270)
- Otolaryngology (333)
- Pain Medicine (307)
- Palliative Medicine (88)
- Pathology (516)
- Pediatrics (1243)
- Primary Care Research (522)
- Public and Global Health (7205)
- Radiology and Imaging (1607)
- Respiratory Medicine (944)
- Rheumatology (461)
- Sports Medicine (403)
- Surgery (514)
- Toxicology (65)
- Transplantation (222)
- Urology (190)